Marc followed his medical training at the Free University in Amsterdam in the Netherlands and got his medical degree in 1994 after which he practiced in vascular surgery and accident and emergency medicine for 6 years. During this time he conducted research in the outcome of carotid endarterectomy and the development of an endoluminal aortic shunt for distal perfusion during thoracic aortal cross-clamping.

Following his medical career Marc joined the International Health Foundation were he lead the research in the use of doping in sport in the Netherlands. After this he joined the pharmaceutical industry as a medical advisor for the atherothrombosis business unit of Sanofi-Synthelabo. In 2004 Marc joined AstraZeneca as a global research physician for cardiovascular development department and was engaged in the CRESTOR clinical development program as well as regulatory defence. Marc moved to Roche in 2008 were he lead the phase 3b development program of the CETP inhibitor and was involved in various other clinical development programs with a focus on dyslipidemia, cardiovascular -, and metabolic disease like PCSK9 and PPARαγ agonism. During his career in the pharmaceutical industry Marc has published various articles in peer reviewed journals.

In February 2014 Marc joined AstraZeneca as a Global Product Vice President for the BRILINTA team in the Global Medicines Development organisation.